Xceleron, the York, UK-based specialist Contract Research Organisation, announced today that they will be providing consultancy services to GlaxoSmithKline to assist in the set up of the pharmaceutical industry’s first in-house Accelerator Mass Spectrometry (AMS) facility. Xceleron currently uses its AMS technology to provide ongoing analytical research services to GlaxoSmithKline, the main aim of which is to help to provide information on human metabolite formation of new drug candidates. GlaxoSmithKline is purchasing two small AMS machines from the National Electrostatics Corporation of Wisconsin, USA to set up two AMS facilities, one in the UK and one in the USA; Xceleron is providing GlaxoSmithKline with consultancy advice. It is GlaxoSmithKline’s intention to use the AMS technology in analysis of samples from early human metabolism studies.
